C44.60 vs D49.2

C44.60 (Unspecified malignant neoplasm of skin of upper limb, including shoulder) compared with D49.2 (Neoplasm of unspecified behavior of bone, soft tissue, and skin), from the official CMS tabular data. C44.60 and D49.2 name the same anatomical site (nail) with a different neoplasm behavior. MedCoder-derived

Relationship

Informational

Neoplasm table relationship

D49.2

Neoplasm of unspecified behavior of bone, soft tissue, and skin

↔

C44.60

Unspecified malignant neoplasm of skin of upper limb, including shoulder

Same anatomical site, different neoplasm behavior.

Same site — primary malignancy (nail)

The behavior documented for the site — malignant primary, secondary, carcinoma in situ, benign, uncertain or unspecified — decides which column of the neoplasm table, and therefore which code, applies.

Source: CMS Table of Neoplasms

Can these codes be reported together?

Same site, different neoplasm behavior. D49.2 and C44.60 name the same anatomical site (nail) with a different neoplasm behavior.

From the CMS/CDC Table of Neoplasms: the behavior documented for that site — malignant primary, secondary, carcinoma in situ, benign, uncertain or unspecified — decides which column, and therefore which code, applies.

Side by side

	C44.60Unspecified malignant neoplasm of skin of upper limb, including shoulder	D49.2Neoplasm of unspecified behavior of bone, soft tissue, and skin
Billing status	Non-billable header Report instead: C44.601, C44.602, C44.609	Billable
Classification	C00-D49 — Neoplasms (C00-D49)	C00-D49 — Neoplasms (C00-D49)
Definition	Unspecified malignant neoplasm of skin of upper limb, including shoulder is a non-billable ICD-10-CM category code (C44.60).	Neoplasm of unspecified behavior of bone, soft tissue, and skin is a billable ICD-10-CM diagnosis code (D49.2).
Includes	malignant neoplasm of sebaceous glands malignant neoplasm of sweat glands	'growth' NOS neoplasm NOS new growth NOS tumor NOS

Edit this comparison Check a whole claim

Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources